49 Clinical Outcomes and Survival Analysis of IDH1-Mutant Grade 4 Astrocytoma: A Retrospective Review in NHS Tayside (2018-2025)
Clicks: 3
ID: 326817
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #204 of 219 articles by views in journal of neuro-oncology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 219 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction IDH1-mutant Grade 4 astrocytoma’s are associated with younger age and superior prognosis compared to IDH wildtype glioblastoma. However long-term outcomes remain variable. We evaluate outcomes, treatment tolerance, and survival within NHS Tayside. Methods Retrospective review of IDH1-mutant grade 4 astrocytoma between 2018 and 2025. Data extracted from NHS database, including demographics, surgery (biopsy vs debulking), MGMT methylation status, adjuvant treatment (Radiotherapy (XRT) and Temozolomide), overall survival, progression free survival, grade 3 or 4 toxicities, recurrence and treatment after recurrence. Results Eight patients identified. Median age 36 years (range 20-59, M:F 3:1). Surgical intervention: gross total debulking (50%), partial debulking (25%) and biopsy alone (25%). All patients (100%) had adjuvant therapy; TMZ alone (12.5%), combination XRT and TMZ (87.5%). No toxicities grade 3 or above from XRT and TMZ. 87.5% suffered disease recurrence and underwent further treatment. Overall, median progression free survival (PFS) was 16 months, and median overall survival (OS)was 38 months. 50% of the cohort remains alive. Conclusion IDH1 mutant grade 4 astrocytoma’s affect a young demographic in NHS Tayside. Adjuvant therapy was well tolerated; high recurrence rate and 16-month PFS underscore aggressive nature of this tumour. Median OS (38 months) surpasses 14.6 median OS in Stupp trial, where IDH1 status was unknown. A study of IDHI1mut Grade 4 astrocytoma by Lasica et al, 2025 reports median OS of 71 months. Age > 50 and CDKN2A/B deletion are significant negative prognosticators for OS. Going forward, review of high-risk molecular markers such as CDKN2A/B homozygous deletion, will better risk-stratify our patients and help tailor treatment.
| Reference Key |
openalex_W7204484645
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mustafa Shah, Hannah Lord |
| Journal | journal of neuro-oncology |
| Year | 2026 |
| DOI |
10.1093/neuonc/noag172.084
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.